Opening and closing kinematics of fresh and calcified aortic valve prostheses: An in vitro study  by Bakhtiary, Farhad et al.
O
a
F
A
Bakhtiary et al Surgery for Acquired Cardiovascular Diseasepening and closing kinematics of fresh and calcified
ortic valve prostheses: An in vitro study
arhad Bakhtiary, MD,a Omer Dzemali, MD,a Ulrich Steinseiffer, PhD,b Christof Schmitz, PhD,b Birgit Glasmacher, PhD,bnton Moritz, MD, PhD,a and Peter Kleine, MD, PhDa
O
b
c
c
M
a
v
c
c
s
t
p
R
e
H
w
s
v
f
U
C
w
c
w
p
c
T
m
a
w
n
m
a
a
i
A
CDFrom the Department of Thoracic and Car-
diovascular Surgery of Johann Wolfgang
Goethe University Hospital,a Frankfurt/
Main, Germany; and Cardiovascular Engi-
neering Group, Helmholtz Institute,b Aachen,
Germany.
This work was supported in part by
Medtronic Inc, Minneapolis, Minn.
Received for publication Nov 16, 2006; re-
visions received Feb 18, 2007; accepted for
publication Feb 23, 2007.
Address for reprints: Farhad Bakhtiary,
MD, Department of Thoracic and Cardio-
vascular Surgery, Johann Wolfgang Geothe
University Hospital, Theodor-Stern-Kai 7,
60596 Frankfurt/Main, Germany (E-mail:
farhad@bakhtiary.de).
J Thorac Cardiovasc Surg 2007;134:657-62
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgeryb
doi:10.1016/j.jtcvs.2007.02.050bjectives: In vitro testing of biologic valves has been performed using only fresh
ut treated valves suitable for patient implantation. The present study investigates
hanges in hemodynamic performance and leaflet kinematics in progressively
alcified porcine and pericardial aortic valve prostheses.
ethods: Edwards Perimount Magna (Edwards Lifesciences, Irvine, Calif) (n  5)
nd Medtronic Mosaic Ultra (Medtronic Inc, Minneapolis, Minn) (n  5) heart
alves (23 mm) were investigated in an artificial circulation system (70 beats/min,
ardiac output 5 L/min). Leaflet kinematics were visualized with a high-speed
amera (3000 frames/sec). Valves were then exposed to a calcium-phosphate
olution at a constant pulse rate of 300 beats/min for a total of 6 weeks. Repeated
esting was performed after 1, 2, 3, 4, and 6 weeks of calcification. The calcification
rocess might not be similar to in vivo performance.
esults: Initially, the Perimount Magna valves demonstrated lower pressure gradi-
nts compared with the Mosaic Ultra valves (9.7 0.36 mm Hg vs 14.0 1.16 mm
g), but they showed higher closing volume and leakage flow. Total energy loss
as equivalent after 1 week of calcification. Perimount Magna valves calcified
ignificantly faster and more severely, leading to an increase in gradients and closure
olume. Leaflet kinematics showed progressively longer opening and closing times
or the pericardial valves (closing time Perimount Magna 135 11 msec vs Mosaic
ltra 85  9 msec after 6 weeks).
onclusions: On the basis of visual inspection, despite the new ThermaFix (Ed-
ards Lifesciences) tissue treatment, the Perimount Magna pericardial valves cal-
ified in vitro faster and more severely than did the Mosaic Ultra porcine valves,
hich demonstrated a more constant performance throughout the calcification
rocess. Leaflet kinematics showed a progressive prolongation of opening and
losing times for pericardial valves, leading to higher closing volume.
he primary function of aortic valves is prevention of backward flow from the
aorta into the left ventricle (LV) during diastolic relaxation. However,
investigations of aortic valve replacement, especially in vivo studies, focus
ainly on forward flow and consider transvalvular gradients and effective orifice
rea (EOA) the most important determinants of prosthetic valve performance,1-4
hereas the diastolic characteristics such as closing volume and leakage flow have
ot been investigated in such detail. The focus on systolic performance led to recent
odifications of biologic aortic valves aimed at maximal valve opening without
ttention to the consequences for valve closure. This limited view on prosthetic
ortic valve function is partly attributable to a lack of methods to study valve closure
n vivo. Therefore, in vitro studies still play an important role in the investigation of
iologic aortic valve prostheses.5-7
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A
CDIn vitro studies have some inherent limitations, such as
onphysiologic contraction of the artificial LV, with the
onsequence of an abnormal flow pattern through the aortic
alve. In addition, only fresh biologic valve prostheses were
nvestigated for hemodynamic performance in vitro,
hereas changes in leaflet motion caused by progressive
egeneration will contribute to the increased mortality after
ortic valve replacement compared with the background
opulation.8,9
The aim of the present study was to achieve a more
omplete view of biologic valve function. We investigated
he hemodynamic performance and durability of 2 biologic
alves (1 porcine and 1 pericardial prosthesis), especially
ocusing on leaflet kinematics and its consequences for
alve opening and closure. Fresh and progressively degen-
rated valves were tested in an in vitro setup. The 2 selected
alves represented the most recent supraannular modifica-
ions of well-known aortic valve substitutes aiming in max-
mization of EOA.
aterials and Methods
he study was performed in cooperation between the Department
f Thoracic and Cardiovascular Surgery at the J. W. Goethe
niversity Frankfurt am Main, Germany, and the Cardiovascular
ngineering Group at the Helmholtz Institute Aachen, Germany.
Five porcine (Mosaic Ultra, Medtronic Inc, Minneapolis, Minn)
nd 5 pericardial (Carpentier Edwards Perimount Magna, Edwards
ifesciences, Irvine, Calif) aortic valve prostheses, 23 mm in size,
ere tested in a previously described artificial circulation system
Figure 1).10
edtronic Mosaic Ultra
his third-generation biologic valve is a sewing ring modification
f the supra-annular Mosaic valve, which has been available for
ore than a decade. Its characteristics are Physiological Fixation
Medtronic Inc) with zero pressure on the leaflets during the
xation process with glutaraldehyde and anticalcification treat-
ent with alpha-aminooleic acid.
erimount Magna
his latest modification of the extensively studied Perimount valve
s characterized by glutaraldehyde fixation, the new ThermaFix
Edwards Lifesciences) anticalcification treatment, and a true su-
raannular design to maximize EOA.
n Vitro Tests
t a constant hemodynamic level (cardiac output of 5 L/min, 70
eats/min), standard in vitro testing was performed (mean systolic
Abbreviations and Acronyms
EOA effective orifice area
LV  left ventricleressure difference, EOA, closure volume, leakage flow), followed i
58 The Journal of Thoracic and Cardiovascular Surgery ● Septey calculation of systolic, diastolic, and total energy loss. Energy
oss was defined as the time integral of the product of the mean
ystolic gradient and aortic flow during a defined interval such as
ystolic duration (systolic energy loss), closing interval (closing
nergy loss), or leakage duration (leakage energy loss). Energy
oss values are expressed in the percentage of ventricular work
oad.
Leaflet kinematics were recorded using a high-speed camera
300 frames/sec). Three heart cycles were taped for further eval-
ation. The movies were evaluated for beginning and end of leaflet
otion for valve opening (opening time) and beginning and end of
eaflet motion for valve closure (closure time).
alve Calcification
fter the initial test run, all prostheses were incorporated into a
ulse duplicator running at 300 beats/min. The valves were irri-
ated with a calcium-phosphate solution to imitate calcific valve
egeneration. This in vitro method of calcification using calcium-
hosphate at a physiologic pH and temperature has been used and
igure 1. Pulsatile artificial circulation system (position of the
ortic valve, arrow): To create physiologic pressure and volume
ourses, flow resistors (15, 17) and programmable wind kettles
14, 16) are used. The flexible left silicone ventricle (9) and the
igid aortic root (11) simulate physiologic geometry. The volume
xpulsion of the simulated LV is created by electrohydraulic
mpulsion (18). Additional air within the compression housing
7a) serves as variable ventricular compliance. The computer-
ontrolled volume extrusion allows an exact and reproducible
imulation of the physiologic ventricular work.nvestigated previously, demonstrating results comparable to
mber 2007
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A
CDn vivo valve degeneration.11,12 The higher pulse rate accelerates
he calcification process as additional mechanical stress is applied
o the leaflets.
During the first 4 weeks, valves were taken out of the pulse
uplicator weekly to undergo photography, hemodynamic testing,
nd leaflet kinematics recording with the high-speed camera. The
alves were subjected to an additional 2 weeks of calcification and
hen tested as noted above. The valves were then investigated for
alcium uptake within the leaflet tissue.
tatistical Evaluation
or the statistical analysis of baseline characteristics and outcomes
or the 2 valves, the Student t test and Fisher exact test were used.
he results are reported as the mean  standard deviation in text
nd Table 1.
esults
he results are divided into 3 sections: hemodynamic re-
ults, progressive calcification results, and leaflet kinematics
esults.
igure 2. Systolic pressure difference (transvalvular gradients)
or the 2 fresh valves, which are treated valves suitable for
atient implantation. Significantly lower values for fresh pericar-
ial valves (0) were observed compared with the porcine pros-
heses. This difference narrowed during the test period of 6
eeks and was not statistically significant at the 2-, 3-, and
ABLE 1. Opening and closing times of Mosaic Ultra (Medt
ifesciences, Irvine, Calif) valves during progressive calci
Fresh 1
agna
Opening time (msec) 48 10 53  12
osaic
Opening time (msec) 27 6 28  10
agna
Closure time (msec) 111 12 121 14
osaic
Closure time (msec) 74 10 74  9
ll differences between Mosaic and Magna valves are statistically signifi-week measurements. o
The Journal of Thoracicemodynamic Performance
emodynamic testing of the fresh and progressively degen-
rated valve prostheses revealed the following results.
Transvalvular gradients. Systolic pressure difference
emonstrated significantly lower values for fresh Magna
alves (mean 9.7  0.36 mm Hg) compared with the fresh
ltra prostheses (mean 14.0 1.16 mm Hg) (P .05). This
ifference narrowed during the test period of 6 weeks and
as not statistically significant at the 2-, 3-, and 6-week
easurements (Figure 2).
Effective orifice area. EOA was significantly larger for
resh Magna valves (1.88  0.06 cm2 vs 1.46  0.08 cm2,
 .01); this difference also narrowed during the experi-
ental period but remained statistically significant (P .05
or the remaining measurements) (Figure 3).
Closure volume. Closure volume was significantly
ower for the fresh Mosaic valves (0.39 0.08 mL vs 1.65
.11 mL, P  .001). This difference remained highly sig-
ificant (P  .001) throughout the entire degeneration pe-
iod. If leakage flow through the closed valve (closing
olume) is also considered, this difference was even more
ronounced (1.3  0.11 mL for fresh Mosaic vs 5.1  0.31
L for Magna valves) (Figure 4).
c Inc, Minneapolis, Minn) and Perimount Magna (Edwards
ion
2 3 4 6
53  10 54  14 54  12 55  12
26  9 28  10 28  11 28  8
130 15 128 15 133 14 135  16
74  13 76  11 77  13 77  9
(P  .001).
igure 3. EOA demonstrated significantly larger results for peri-
ardial valves throughout the observation period (P < .05), with
ome narrowing with progressive degeneration. EOA, Effectiveroni
ficatrifice area.
and Cardiovascular Surgery ● Volume 134, Number 3 659
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6
A
CDTotal energy loss. The combination of systolic, closure,
nd leakage energy demonstrated comparable results for the
valves (9.2% 1.21% vs 9.6% 1.11%); however, there
as no difference after 1 week. The higher systolic energy
oss of the Mosaic valves and the higher closure and leakage
nergy loss of the Magna valves equalized each other,
eading to almost identical results for the total energy loss
Figure 5).
alve Calcification
agna valves calcified faster and more diffusely compared
ith the Mosaic valves (Figure 6). Even after 1 week of
alcification, 3 of 5 pericardial valves demonstrated visible
eposits of calcium on the leaflet side that was oriented
oward the LV (rough side of the pericardium). After the
omplete 6-week observation period, all Magna valves
emonstrated significant diffuse calcification. Only 1 of 5
osaic valves demonstrated significant calcification of the
eaflets; the remaining prostheses had only minor calcium
eposits at the boundary between the leaflets and the stent.
he amount of calcium uptake in the 2 bioprostheses was
ocumented by the photographs but not objectively mea-
igure 4. Closure volume showed highly significant higher re-
ults for pericardial valves at each point (P < .001).
igure 5. Total energy loss (% of work load) was comparable for
ericardial and porcine valves. A higher systolic energy loss for
he porcine valves was equalized by lower diastolic energyeosses.
60 The Journal of Thoracic and Cardiovascular Surgery ● Septeured, because the study intended to mainly investigate the
mpact of valve calcification on the leaflet kinematics.
eaflet Kinematics
pening and closure times of the 2 valve prostheses are
isted in Table 1. Valve opening was seen at the exact same
ime point for the 2 valves, but beginning of valve clo-
ure was delayed for the pericardial valves. Mosaic porcine
alves opened and closed significantly faster throughout the
omplete observation period of 6 weeks (P .01). Whereas
he leaflet kinematics remained stable for the Mosaic valves,
here was a tendency toward longer opening times and a
ignificant increase in closure times for the pericardial
agna valves. With progressive calcification, 1 of the
agna valves demonstrated an incomplete opening of 1 of
he leaflets at the 6-week high-speed movie investigation.
lmost all pericardial valves showed a small central open-
ng at the coaptation zone of the 3 leaflets, explaining the
ncreased leakage flow (Figure 7).
igure 6. A typical example of leaflet kinematics for both valves,
ericardial (A) and porcine (B), after 3 weeks of degeneration.
igure 7. Incomplete opening of one pericardial leaflet (arrow)
fter 6 weeks of progressive calcification. Mean pressure gradi-
nt in this valve was 18 mm Hg.
mber 2007
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A
CDiscussion
iologic aortic valve replacement has generated increasing
nterest over the past decade, partly because of the aging
atient population and partly because of the reported excel-
ent durability of second- and third-generation biological
alve prostheses.13-15 The 2 major determinants of long-
erm outcome are hemodynamic performance and durability
f the implanted valves.
Most of the commercially available biologic valves consist
ither of porcine aortic leaflets or bovine pericardium. No
andomized studies of patient outcome with large patient num-
ers comparing these 2 designs have been published, but a
endency toward lower transvalvular gradients for the pericar-
ial valves has been reported.13,14 However, some groups
howed that long-term survival seemed to favor the porcine
rostheses.16,17 Factors other than pressure gradients and EOA
ay also contribute significantly to the clinical outcome after
ortic valve replacement.
The present study aimed at gaining a detailed view of
iologic valve performance with the special focus on valve
losure and changes of leaflet kinematics with progressive
alcification. The 2 selected valves were labeled 23 mm;
owever, studies comparing Perimount Magna with
edtronic Mosaic valves demonstrated smaller metric di-
meters for the Mosaic valve, leading to the ability to
mplant larger valve sizes in 28.4% for the porcine valve
ompared with only 8.3% for the pericardial valve.18,19
owever, the authors decided to compare identically la-
eled valve sizes to avoid misunderstanding.
Our study confirmed the excellent systolic performance
f the fresh Magna valve, but this advantage disappeared to
certain extent so that the difference was no longer signif-
cant after 2 weeks of in vitro calcification. This observation
as explained by the fast initiation of the calcification
rocess for the pericardial valves despite the new ThermaFix
nticalcification treatment. The observed increase of sys-
olic pressure differences was also observed in vivo for
tandard Perimount valves by Banbury and colleagues.16
OA also favored the Magna prostheses. The large valve
pening could be observed in the high-speed movies, with
he pericardial leaflets moving completely out of the area of
orward flow. However, this extensive leaflet motion during
alve opening led to the delayed beginning of valve closure
nd significantly longer closure times. As a consequence,
igher closure volumes were seen for the Magna prostheses,
eading to an equivalent total energy loss. Valve incompe-
ence was reported in vivo with transition from Grade 0 or
race to Grade 1, then to Grade 1 or 2, and finally to
rade 3 or 4 (14).
Mosaic valves showed higher transvalvular gradients and
maller EOAs, especially for fresh valves. The high-speed
ovies demonstrated a less-extensive leaflet motion com-ared with the Magna valves, so the systolic energy loss can s
The Journal of Thoracice explained by the tissue and stent material within the
orward flow area. On the other hand, this more physiologic
alve opening led to fast and competent valve closure so
losure volumes matched the results of native human aortic
alves.18 The absence of regurgitation was also reported
linically for standard Mosaic valves.15 The porcine tissue
reated with alpha-aminooleic acid resisted the in vitro
lassification method, so the hemodynamic results remained
lmost stable throughout the experiment. No valve malfunc-
ion could be observed.
On comparison of the 2 valve designs, one might sum-
arize that the Magna pericardial valve was designed for
aximal opening and thus matched the current opinion that
ystolic performance determines valve function and patient
utcome.20-22 The price paid for maximizing the leaflet
ovement away from the coaptation zone is delayed and
low valve closure. If we consider valve closure as the
rimary function of a valve, the Magna valve failed to
imic physiology. It is not surprising that the use of native
orcine valve leaflets in the Mosaic Ultra model led to
eaflet motion closer to physiology. The need for stent
ounting of the leaflets resulted in some restriction of
orward flow leading to higher gradients (maximal differ-
nce of 4 mm Hg), but the leaflet motion allowed earlier and
aster closure.
The main goal in aortic valve replacement is good qual-
ty of life for our patients and a long-term survival compa-
able to that of the background population. This can be
chieved by a valve that imitates a healthy native human
alve and avoids lesions that impact ventricular function
stenosis and regurgitation). First, the primary function has
o be matched: an early, fast, and competent closure. Here,
he porcine Mosaic Ultra valve demonstrated lower regur-
itant flows compared with the pericardial prosthesis. Sec-
nd, the valve opening has to be considered with favorable
esults for the pericardial Magna prosthesis. The investiga-
ion of leaflet kinematics using a high-speed camera deliv-
red the explanation for the systolic and diastolic hemody-
amic results. In regard to the susceptibility to calcification,
he pericardial tissue seemed to show a tendency toward
aster and more severe calcification regarding photographic
ocumentation.
imitations
n vitro calcification of the aortic valves eliminates the
ndividual factor of valve degeneration, which requires
arge patient numbers for in vivo studies. Also, the method
sed in the present study has been verified. However, this is
till an in vitro experiment with all of the limitations. Of
ourse, the process of valve calcification might be different
n the individual patient. The calcification was measured by
isual inspection. The prostheses were of equivalent labeled
izes but necessarily equivalent sizes to fit a similar annulus.
and Cardiovascular Surgery ● Volume 134, Number 3 661
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A
CDThe valves were removed from the calcifying solution
or hemodynamic testing each week, so the calcification
rocess might have been interrupted and thus affected the
utcome. However, this was identical for all valves tested.
follow-up study with calcification for 4 weeks in a row is
lanned. Further investigation is needed to demonstrate the
linical relevance of our findings.
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